Patients with advanced or recurrent endometrial cancer spend about 15% of their time addressing health care needs, and this time burden can have a negative effect on their quality of life, a study suggests.
Adding dostarlimab to chemotherapy can improve outcomes in patients with primary advanced or recurrent endometrial cancer, a phase 3 trial suggests.
Adding pembrolizumab to chemotherapy improves progression-free survival in advanced or recurrent endometrial cancer, a phase 3 trial suggests.
The management of advanced gynecologic cancers remains a challenge, but the treatment landscape is changing.
The accelerated approval for Jemperli (dostarlimab-gxly) was converted to regular approval.
People with type 2 diabetes have an increased risk of death from colorectal, pancreatic, liver, and endometrial cancer, compared with the general population.
Postmenopausal cancer survivors have greater declines in physical function than cancer-free control individuals, a new study suggests.
Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
After adjustment for confounding variables, the risk of endometrial cancer was increased almost 4-fold with tamoxifen treatment.
A retrospective evaluation of lab results linked the likelihood of certain cancer types with the presence of specific pathogenic variants in CHEK2.
